Capricor Therapeutics' shares fell about 67% after FDA reviewers raised concerns about the effectiveness evidence for its experimental Duchenne muscular dystrophy therapy, deramiocel. The FDA criticized changes in the company's trial data analysis and questioned whether the therapy reached the heart sufficiently to provide benefit. The therapy is under review with a decision expected by August 22, with no current FDA-approved treatments specifically for Duchenne-related heart issues. Capricor remains confident in its therapy despite the FDA's concerns.
A Vice President at WM sold 1,365 shares valued at $300,000. Insider sales like this can indicate the executive's personal financial decisions but do not necessarily reflect the company's outlook. Investors should watch for any further insider activi...
Uniswap drives more than 99% of stock-token deposits into Robinhood Chain, making it the primary gateway for tokenized equity on the network during its early phase. This dominance reflects Uniswap's deep liquidity pools and structural advantage as a ...
The Florida Chamber of Commerce launched a billboard campaign in Chicago criticizing Illinois Governor JB Pritzker for policies they say are driving businesses and residents out of Illinois to Florida. The campaign highlights billions in taxable inco...
Oil prices fell as U.S. officials held a three-hour meeting with Iran's delegation, raising hopes for a diplomatic resolution to Middle East conflicts. Brent crude dropped 0.75% to $98.51 per barrel, while U.S. West Texas Intermediate fell 1.03% to $...
Enterprise Products Partners (EPD), a major midstream energy company with over $80 billion in market value, has outperformed the S&P 500 by nearly 35% due to rising energy demand. The company's future growth depends on continued energy consumption, b...
